<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380415</url>
  </required_header>
  <id_info>
    <org_study_id>129-0469-01</org_study_id>
    <nct_id>NCT04380415</nct_id>
  </id_info>
  <brief_title>Validation of Software for Assessment of Atrial Fibrillation From PPG Data Acquired by a Wearable Smartwatch</brief_title>
  <official_title>Fitbit Atrial Fibrillation From PPG Data Validation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fitbit Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fitbit Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Validate the Fitbit PPG RhythmDetect Software System algorithm for providing notifications by
      identifying rhythms suggestive of atrial fibrillation or atrial flutter events.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the ability of an irregular heart rhythm detection algorithm to identify a rhythm suggestive of atrial fibrillation or atrial flutter (AF) during simultaneous wear of an ECG patch monitor.</measure>
    <time_frame>7 days</time_frame>
    <description>Positive predictive value (PPV) of the irregular heart rhythm detection algorithm, using physician interpreted ECG patch results as the clinical reference, during the ECG patch monitoring period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the ability of an irregular heart rhythm detection algorithm to identify a rhythm suggestive of AF in analyzable spot tachograms (overlapping 5- minute intervals), compared with an ECG patch monitor.</measure>
    <time_frame>7 days</time_frame>
    <description>Proportion of positive tachograms with AF episodes â‰¥ 30 seconds during a positive irregular heart rhythm detection, using physician-interpreted ECG during the same time periods as the clinical reference.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Detection Notification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulse rate data will be collected from a commercial device worn on the wrist. ECG will be collected from a single lead ambulatory ECG patch worn on the chest. The data from both the commercial wrist-worn device and the ECG patch are not analyzed real-time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Detection Notification</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Pulse rate data will be collected from a commercial device worn on the wrist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Single lead ambulatory ECG patch</intervention_name>
    <description>Single lead ambulatory ECG patch worn on the chest</description>
    <arm_group_label>Detection Notification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 22 years of age or older

          -  Capable of giving informed consent

          -  U.S. resident

          -  No prior history of atrial fibrillation or atrial flutter

          -  General Population cohort: PPG enabled device (Ionic, Charge 3, Versa, Versa Lite,
             Versa 2, Inspire HR)

        Exclusion Criteria:

          -  Diagnosis or history of Atrial Fibrillation at time of consent

          -  Diagnosis or history of Atrial Flutter at time of consent

          -  Current use of anticoagulation medication

          -  Cardiac pacemaker or implantable cardioverter-defibrillator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Lubitz, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony Faranesh, PhD</last_name>
    <phone>415-513-1000</phone>
    <email>tfaranesh@fitbit.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PlushCare</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Wantuck, MD</last_name>
      <phone>888-713-5540</phone>
      <email>jwantuck@plushcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

